COVID-19 Vaccine Induced Adaptive Immune Responses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-27

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 million confirmed cases and caused around 1.8 million deaths, as of 2 January 2021. The ongoing pandemic still poses unprecedented global threat to public health system worldwide. On December 31, 2020, the joint prevention and control agency of China Council announced that Sinopharm SARS-CoV-2 inactivated vaccine had been conditionally approved by National Medical Products Administration, and the protection rate was 79.34%. So far, more than 198 vaccines were currently in preclinical or clinical development. The investigators aimed to initiate an observational cohort of healthy individuals injected with SARS-CoV-2 Vaccine, which will perform a longitudinal, comprehensive analysis of the SARS-CoV-2 vaccine Induced adaptive immune responses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Responses to COVID-19 Infection or Vaccination

NCT05379478

COVID-19

COMPLETED

Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers

NCT05049187

Covid19

COMPLETED

A Study of Immune Responses to the Virus That Causes COVID-19

NCT04431414

SARS-CoV-2 COVID-19

COMPLETED

Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease

NCT05043246

Diseases, Chronic Covid19 Adverse Reaction to Vaccine

UNKNOWN

Understanding Immunity to the COVID-19 Vaccines

NCT04664309

COVID-19 Immunity Vaccine

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 Vaccine COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy and aged between 18 to 59 years

Exclusion Criteria

* High-risk epidemiology history within 14 days before enrollment
* SARS-CoV-2 specific IgG or IgM positive in serum
* Positive PCR test for SARS-CoV-2 from pharyngeal or anal swab samples
* Axillary temperature of more than 37·0°C
* Known allergy to any vaccine component
* Thyroid disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes